Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

25.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 25.09
Bid (Size) 20.03 (5)
Ask (Size) 27.60 (1)
Prev. Close 25.09
Today's Range 25.09 - 25.09
52wk Range 13.59 - 26.13
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga

Performance

YTD
+10.09%
+10.09%
1 Month
+5.82%
+5.82%
3 Month
+28.47%
+28.47%
6 Month
+52.06%
+52.06%
1 Year
+30.13%
+30.13%

More News

Read More
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Via Benzinga
7 Biotech Stocks to Buy for Q3
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Via Benzinga
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Via Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
Via Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Via Benzinga
5 Stocks To Watch For December 23, 2021
Via Benzinga
Is Now the Time to Bet on Arcutis Biotherapeutics?
Via The Motley Fool
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Via Benzinga
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.